Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy
Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy
The purpose of the protocol is to determine the effect of BN83495 on the progression of
 endometrial cancer with estrogen receptor in post menopausal women who had previously
 received chemotherapy.
Inclusion Criteria:

 -  Provision of written informed consent prior to any study related procedures.

 -  postmenopausal or ovariectomised female patient over 18 years of age.

 -  histologically confirmed diagnosis of ER positive endometrial carcinoma in the primary
 tumour or metastatic disease

 -  patient has received one line of chemotherapy prior to enrolment in the adjuvant or in
 the metastatic setting (including chemoradiotherapy) and progressed after this line of
 chemotherapy

 -  patient has at least one measurable disease site (RECIST criteria version 1.1)

 Exclusion Criteria:

 -  patient has received hormone therapy for endometrial cancer in the adjuvant or
 metastatic setting

 -  patient has received more than one line of chemotherapy in the adjuvant or metastatic
 setting

 -  patient was treated with any other investigational agent within the 3 weeks before
 study entry.

 -  patient has ongoing cardiac dysrhythmias grade ≥2, atrial fibrillation of any grade
 (NCI CTCAE) or QTcF interval >460 msec.